MNKD Latest Press Releases

-- October 29, 2026 --

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 Globe Newswire 4:01 PM

-- October 14, 2026 --

MannKind to Participate in the Chardan Healthcare Conference Globe Newswire 4:01 PM

-- October 9, 2026 --

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) Globe Newswire 8:00 PM

-- September 9, 2026 --

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management Globe Newswire 6:30 AM

-- September 2, 2026 --

MannKind to Present at Upcoming Investor Conferences Globe Newswire 8:30 AM

-- August 5, 2026 --

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM

-- July 29, 2026 --

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF Globe Newswire 6:30 AM

-- July 28, 2026 --

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026 Globe Newswire 4:01 PM

-- July 24, 2026 --

MannKind Announces $50 Million Private Placement Globe Newswire 6:35 AM

MannKind Announces FDA Approval of Furoscix ReadyFlow , the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease Globe Newswire 6:30 AM

-- June 23, 2026 --

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D Globe Newswire 9:00 AM

-- June 5, 2026 --

Data at ADA 2026 Highlights Key Findings from Clinical and Real-World Studies of MannKind's Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems Globe Newswire 7:35 PM

-- June 3, 2026 --

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF Globe Newswire 6:05 AM

Market Data Delayed 15 Minutes